Cell and Gene Therapy Contract Development and Manufacturing Organizations, 2022: Frost Radar Report

A Benchmarking System to Spark Companies to Action-Innovation that Fuels New Deal Flow and Growth Pipelines

As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treatment. Some organizations double up as hybrid CDMOs and incubators.
They have their own pipelines, but they also partner with other companies to support and accelerate development.

Contract development and manufacturing organizations (CDMOs) and CROs are expanding organically and inorganically to provide end-to-end CGT services. More than 100 companies compete in the CGT CDMO marketplace globally, and most specialize in either cell therapy or gene therapy. Only a handful offer diversified services. CDMOs are increasingly distinguishing themselves from their competitors and have redefined themselves as contract research, development, and manufacturing organizations (CRDMOs) and have integrated themselves into companies’
value chains.

The Frost Radar™ reveals the market positioning of companies in an industry using their Growth and Innovation scores as highlighted in the
Frost Radar™ methodology. The document presents competitive profiles of each of the companies in the Frost Radar™ based on their strengths, opportunities, and a small discussion on their positioning. The analyst analyzes hundreds of companies in an industry and benchmarks them across 10 criteria on the Frost Radar™, where the leading companies in the industry are then positioned.